FrancophonIA/ELRC3.0 huggingface dataset:
English: AUC12h: ↔ Cmax: ↔
Estonian: Maraviroc: AUC12h: ↔
English: Simvastatin/Efavirenz (40 mg q.d./600 mg q.d.)
Estonian: Simvastatiin/efavirens (40 mg q.d./600 mg q.d.)
English: -3.3 (-8.3% to 2.7%) patients with HIV-1 RNA < 200 copies/ml
Estonian: patsiendid HIV-1 RNA tasemega < 200 koopiat/ml
English: - methadone (used to treat opiate addiction)
Estonian: Didanosiini sisaldavad ravimid (HIV-infektsiooni raviks).
English: However, malformations were observed in 3 of 20 foetuses/newborns from efavirenz-treated cynomolgus monkeys given doses resulting in plasma efavirenz concentrations similar to those seen in humans.
Estonian: Makaakidel, kellele manustati efavirensi annuseid, mille korral plasmakontsentratsioonid olid võrdväärsed inimestel saavutatuga, leiti aga 3 lootel/vastsündinul 20-st väärarenguid.
English: Itraconazole/Tenofovir disoproxil
Estonian: Itrakonasool/ tenofoviirdisoproksiil
English: Dosage adjustments of pravastatin may be required when co-administered with Atripla (refer to the Summary of Product Characteristics for pravastatin).
Estonian: Pravastatiini taseme kohandamine võib olla vajalik koos Atripla'ga manustamisel (vt simvastatiini ravimi omaduste kokkuvõte).
English: Caution must be taken in any patient with a history of seizures.
Estonian: Krambianamneesiga patsientide puhul peab olema ettevaatlik.
English: N-monodesmethyl diltiazem: AUC: ↓ 37% (↓ 17 to ↓ 52)
Estonian: Hüdroksüitrakonasool: AUC: ↓ 37% (↓ 14...↓ 55)
English: AUC: ↓ 83% (↓ 79 to ↓ 87) Cmax: ↓ 80% (↓ 77 to ↓ 83) Cmin: ↓ 86% (↓ 80 to ↓ 90)
Estonian: Cmax: ↓ 80% (↓ 77 to ↓ 83)
English: AUC: ↓ 36% C12h: ↓ 21% Cmax: ↓ 36%
Estonian: Raltegraviir: AUC: ↓ 36% C12h: ↓ 21%
English: Oral use.
Estonian: Annuse kohandamine.
English: • itchy rash to the skin caused by a reaction to sunlight
Estonian: • sügelev nahalööve kokkupuutel päikesevalgusega.
English: Co-administration of lopinavir/ritonavir and Atripla is not recommended.
Estonian: Lopinaviiri/ritonaviiri manustamist koos Atripla'ga ei soovitata.
English: AUC: ↔*/** (↓ 10% to ↑ 26%) Cmax: ↔*/** (↓ 5% to ↑ 26%) Cmin: ↑ 12%*/** (↓ 16 to ↑ 49)
Estonian: Cmax: ↔*/** (↓ 5% to ↑ 26%)
English: Morning AUC: ↑ 18% (↑ 6 to ↑ 33) Evening AUC: ↔ Morning Cmax: ↑ 24% (↑ 12 to ↑ 38)
Estonian: Hommikune AUC: ↑ 18% (↑ 6...↑ 33) Õhtune AUC: ↔
English: The following side effects are uncommon (these may affect up to 1 in every 100 patients):
Estonian: Järgmised kõrvaltoimed esinevad aeg-ajalt (võivad esineda kuni 1 patsiendil 100-st):
English: Sofosbuvir/Velpatasvir/Voxilaprevir (400 mg/100 mg/100 mg q.d.)
Estonian: Sofosbuviir/velpatasviir/ voksilapreviir (400 mg/100 mg/100 mg 1 kord ööpäevas) +
English: ANTICONVULSANTS Carbamazepine/Efavirenz (400 mg q.d./600 mg q.d.)
Estonian: ANTIKONVULSANDID Karbamasepiin/efavirens (400 mg q.d./600 mg q.d.)
English: Voriconazole: Co-administration of standard doses of efavirenz and voriconazole is contraindicated.
Estonian: Efavirensi ja vorikonasooli tavaliste annuste koosmanustamine on vastunäidustatud.
English: AUC: ↑ 44% Cmax: ↑ 38%
Estonian: Cmax: ↑ 38%
English: (mechanism of interaction unknown) Tenofovir:
Estonian: (koostoime mehhanism teadmata)
English: Ethinyloestradiol:
Estonian: Vorikonasool.
English: Atorvastatin/Tenofovir disoproxil
Estonian: Atorvastatiin/ tenofoviirdisoproksiil
English: The pharmacokinetics of Atripla have not been studied in HIV infected patients with hepatic impairment.
Estonian: Maksakahjustuse ja HIV-infektsiooniga patsientidel ei ole Atripla farmakokineetikat uuritud.
English: AUC: ↑ 34% (↑ 18 to ↑ 53) Cmax: ↑ 49% (↑ 32 to ↑ 69)
Estonian: Cmax: ↑ 49% (↑ 32...↑ 69)
English: Itraconazole/Efavirenz (200 mg b.i.d./600 mg q.d.)
Estonian: Seentevastased ravimid Itrakonasool/efavirens (200 mg b.i.d./mg 600 q.d.)
English: Voriconazole/Tenofovir disoproxil
Estonian: Vorikonasool/ tenofoviirdisoproksiil
English: AUC: ↓ 58% (↓ 39 to ↓ 68) Cmax: ↓ 51% (↓ 32 to ↓ 58)
Estonian: Cmax: ↓ 51% (↓ 32...↓ 58)
English: Modified LOCF 190/203 (93.6%)
Estonian: M= ebaefektiivsus 181/203 (89,2%)
English: Fosamprenavir/ritonavir/Emtricitabine
Estonian: Fosamprenaviir/ritonaviir/emtritsi tabiin
English: Clarithromycin/Efavirenz (500 mg b.i.d./400 mg q.d.)
Estonian: Antibiootikumid Klaritromütsiin/efavirens (500 mg b.i.d./400 mg q.d.)
English: Uncommon rhabdomyolysis2, muscular weakness2
Estonian: Aeg-ajalt rabdomüolüüs2, lihasnõrkus2
English: Rifampicin/Efavirenz (600 mg q.d./600 mg q.d.)
Estonian: Rifampitsiin/efavirens (600 mg q.d./600 mg q.d.)
English: Cmax: ↓ 64% (↓ 57 to ↓ 69) Cmin: ↓ 62% (↓ 44 to ↓ 75)
Estonian: Cmax: ↓ 64% (↓ 57...↓ 69)
English: Treatment group
Estonian: Erirühmad
English: Darunavir/ritonavir/Emtricitabine
Estonian: Sakvinaviir/ritonaviir/emtritsitabii n
English: Atazanavir/ritonavir: Insufficient data are available to make a dosing recommendation for atazanavir/ritonavir in combination with Atripla.
Estonian: Puuduvad piisavad andmed, et anda annustamissoovitust atazanaviiri/ritonaviiri kasutamisel kombinatsioonis Atripla'ga.
English: • pain in the abdomen (stomach), caused by inflammation of the pancreas
Estonian: • kõhunäärmepõletikust põhjustatud kõhuvalu
English: AUC: ↓ 46% Cmax: ↓ 38%
Estonian: Cmax: ↓ 38%
English: The pharmacokinetics of efavirenz have not been studied in patients with renal impairment.
Estonian: Neerukahjustusega patsientidel ei ole efavirensi farmakokineetikat uuritud.
English: Paediatric population
Estonian: Õhuke polümeerikate
English: AUC: ↓ 35% (↓ 13 to ↓ 40) Cmax: ↓ 13% (↓ 0 to ↓ 23)
Estonian: Cmax: ↓ 13% (↓ 0...↓ 23)
English: Paroxetine:
Estonian: Efavirens:
English: Simeprevir/Emtricitabine
Estonian: Simepreviir/emtritsitabiin
English: Renal impairment
Estonian: Harv laktaadi atsidoos
English: [outer packaging only]
Estonian: [ainult välispakend] 18.
English: AUC: ↓ 60% (↓ 52 to ↓ 68) Cmax: ↓ 62% (↓ 55 to ↓ 78)
Estonian: Cmax: ↓ 62% (↓ 55...↓ 78)
English: The pharmacokinetics of Atripla have not been studied in patients with hepatic impairment.
Estonian: Maksakahjustusega patsientidel ei ole Atripla farmakokineetikat uuritud.
English: AUC: ↓ 54% Cmax: ↓ 45%
Estonian: Cmax: ↓ 45%
English: Clarithromycin/Tenofovir disoproxil
Estonian: Klaritromütsiin/ tenofoviirdisoproksiil
English: NRTIs and NNRTIs NRTIs/Efavirenz
Estonian: NRTId ja NNRTId NRTId/efavirens
English: AUC: ↓ 40% (↓ 26 to ↓ 57) Cmax: ↓ 18% (↓ 59 to ↑ 12)
Estonian: Cmax: ↓ 18% (↓ 59...↑ 12)
English: Norelgestromin (active metabolite):
Estonian: Naistepuna ürt (Hypericum perforatum).
English: Your doctor may consider giving you the components of Atripla separately if you are having problems or need your dose adjusted.
Estonian: Kui teil on probleeme või kui teie annus vajab korrigeerimist, võib arst määrata teile Atripla toimeained eraldi preparaatidena.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
Estonian: VÄLISPAKENDIL JA SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED PUDELI JA KARBI MÄRGISTUS
English: AUC: ↓ 4% (↓ 0 to ↓ 31) Cmax: ↓ 47% (↓ 9 to ↓ 51)
Estonian: Cmax: ↓ 47% (↓ 9...↓ 51)
English: Atovaquone and proguanil hydrochloride/Efavirenz (250/100 mg single dose/600 mg q.d.)
Estonian: Atovakuoon ja proguaniilvesinikkloriid/efavirens (250/100 mg ühekordne annus/600 mg päevas)
English: Plasma levels of efavirenz can be reduced by concomitant use of St. John's wort due to induction of drug metabolising enzymes and/or transport proteins by St. John's wort.
Estonian: See on tingitud ravimeid metaboliseerivate ensüümide ja/või transportvalkude induktsioonist naistepuna toimel.
English: Pravastatin/Tenofovir disoproxil
Estonian: Pravastatiin/ tenofoviirdisoproksiil
English: Hepatic impairment
Estonian: Aeg-ajalt äge hepatiit
English: AUC12h: ↓ 45% (↓ 38 to ↓ 51) Cmax: ↓ 51% (↓ 37 to ↓ 62)
Estonian: Maraviroc: AUC12h: ↓ 45% (↓ 38 kuni ↓ 51)
English: AUC: ↓ 77% Cmax: ↓ 61%
Estonian: Cmax: ↓ 61%
English: AUCinf
Estonian: Sugu
English: Simvastatin acid:
Estonian: Naatriumlarüülsulfaat
English: Hepatic events
Estonian: KLIINILISED ANDMED
English: 6 years.
Estonian: 6 aastat.
English: • The other ingredients are
Estonian: • Teised koostisosad on
English: The clinical significance of this substitution is currently unknown.
Estonian: Selle asenduse kliiniline tähendus on käesolevalt teadmata.
English: (may affect more than 1 in 10 people)
Estonian: (võivad esineda enam kui ühel inimesel 10st)
English: The table is not all-inclusive.
Estonian: Tabel ei ole kõikehõlmav.
English: • If you are currently taking any of the following medicines:
Estonian: • Kui te võtate hetkel ükskõik millist järgmistest ravimitest:
English: Study 1119
Estonian: Uuring 1119
English: Use only if no other alternative is available.
Estonian: Kasutada ainult teiste alternatiivide puudumisel.
English: SVR12 was achieved in 18/18 patients.
Estonian: SVR12 saavutati 18/18 patsiendil.
English: Date of first authorisation: 17 November 2014 Date of latest renewal: 01 August 2019
Estonian: Müügiloa esmase väljastamise kuupäev: 17. november 2014 Müügiloa viimase uuendamise kuupäev: 01. august 2019
English: Treatment duration was fixed in each study.
Estonian: Ravi kestus fikseeriti iga uuringu jaoks eraldi.
English: NS: not studied.
Estonian: NS: ei ole uuritud.
English: > or = 75
Estonian: > või = 75
English: Effects of food
Estonian: Toidu mõju
English: Keep the tablet bottle with you so that you can easily describe what you have taken.
Estonian: Võtke tabletipudel kaasa, nii saate hõlpsalt kirjeldada, mida te olete võtnud.
English: Ribavirin can be very damaging to an unborn baby.
Estonian: Ribaviriin võib teie sündimata lapsele tõsist kahju tekitada.
English: The two studies were identical in study design.
Estonian: Kaks uuringut olid ülesehituselt identsed.
English: The frequency of the following side effects is not known (frequency cannot be estimated from the available data).
Estonian: Järgmiste kõrvaltoimete esinemissagedus on teadmata (sagedust ei saa hinnata olemasolevate andmete alusel).
English: Summary of the safety profile in adults
Estonian: Ohutusprofiili kokkuvõte täiskasvanutel
English: The active metabolite is not observed.
Estonian: Aktiivset metaboliiti ei ole täheldatud.
English: The most common variant was Y93H.
Estonian: Kõige sagedamini esinenud variant oli Y93H.
English: Stable replicons
Estonian: Stabiilsed replikonid
English: The recommended dose is one tablet once a day.
Estonian: Soovitatav annus on üks tablett üks kord ööpäevas.
English: Patients should be instructed not to take a double dose.
Estonian: Patsiente tuleb juhendada, et kahekordset annust ei tohi võtta.
English: Do not take a double dose (two doses close together).
Estonian: Ärge võtke kahekordset annust (kaks annust väikeste vahedega).
English: No effect = 1.00. b All interaction studies conducted in healthy volunteers.
Estonian: Toime puudub = 1,00. b. Kõik koostoimeuuringud on läbi viidud tervetel vabatahtlikel.
English: The majority of patients (84%) had been infected through vertical transmission.
Estonian: Enamik patsiente (84%) oli saanud nakkuse vertikaalse nakatumise teel.
English: The tablet is 19 mm long and 10 mm wide.
Estonian: Tablett on 19 mm pikk ja 10 mm lai.
English: Like all medicines, this medicine may cause side effects.
Estonian: Nagu kõik ravimid, võib ka see ravim põhjustada kõrvaltoimeid.
English: Ribavirin was discontinued in 15% of the patients.
Estonian: Ribaviriini manustamine katkestati 15% patsientidest.
English: Consequently, consideration should be given to longer treatment for patients with uncertain subsequent retreatment options.
Estonian: Järelikult tuleb kaaluda pikemat ravi patsientidel, kelle järgneva kordusravi võimalused ei ole kindlad.
English: Do not chew, crush or split the tablet as it has a very bitter taste.
Estonian: Ärge tabletti närige, purustage ega poolitage, kuna see on väga kibeda maitsega.
English: Ledipasvir is > 99.8% bound to human plasma proteins.
Estonian: Ledipasviir seondub > 99,8% ulatuses inimese plasmavalkudega.
English: Do not use this medicine after the expiry date which is stated on the bottle and carton after “EXP”.
Estonian: Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud pudelil ja karbil pärast „EXP”.
English: It is very important that you read the “Pregnancy” section in the ribavirin package leaflet very carefully.
Estonian: On väga oluline, et te loete eriti hoolikalt ribaviriini pakendi infolehe lõiku „Rasedus”.
English: Fifty-five percent (55%) of the patients were treatment-experienced.
Estonian: Viiskümmend viis protsenti (55%) patsientidest olid varem ravitud.
English: These should be taken at least 4 hours before or 4 hours after Harvoni;
Estonian: Neid tuleb võtta vähemalt 4 tundi enne või 4 tundi pärast Harvonit;
English: • Your doctor can decide if you should take Harvoni and for how long;
Estonian: • teie arst saaks välja selgitada, kas te peate Harvonit võtma ja kui kaua;
English: Do not stop taking Harvoni
Estonian: Ärge lõpetage Harvoni võtmist
English: Study 1468 (LEPTON)
Estonian: Uuring 1468 (LEPTON) Uuring 1119
English: < 12 g/dL despite 4 weeks at reduced dose
Estonian: < 12 g/dl vaatamata annuse vähendamisele 4 nädala jooksul
English: • Your doctor can confirm that your treatment has worked and you are free of the hepatitis C
Estonian: • teie arst saaks kinnitada ravi toimimist ja et olete C-hepatiidi viirusest vabanenud.
English: • you have diabetes.
Estonian: • teil on diabeet.
English: The use of Harvoni in children has not yet been studied.
Estonian: Harvoni kasutamist lastel ei ole veel uuritud.
English: Age (years): median (range)
Estonian: Vanus (aastad): mediaan (vahemik)
English: Limited data indicate that such NS5A mutations do not revert on long-term follow-up.
Estonian: Piiratud andmed näitavad, et sellised NS5A mutatsioonid ei taandu pikaajalisel järelkontrollil.
English: e These are drugs within class where similar interactions could be predicted.
Estonian: e. Need on sellesse klassi kuuluvad ravimid, kus sarnased kõrvaltoimed on ette ennustatavad.
English: Treatment and duration
Estonian: Ravi ja kestus
English: Famotidine dosed 12 hours prior to Harvonid
Estonian: Famotidiin manustatud 12 tundi enne Harvonitd
English: Do not drive or operate machines if you feel tired after taking your medicine.
Estonian: Ärge juhtige autot ega kasutage masinaid, kui teil tekib pärast ravimi võtmist väsimustunne.
English: Your doctor will tell you for how many weeks you should take Harvoni.
Estonian: Teie arst ütleb teile, mitu nädalat te peate Harvonit võtma.
English: Patients who are identified as being high risk of bradyarrhythmia should be continuously monitored for 48 hours in an appropriate clinical setting.
Estonian: Patsiente, kellel on kõrge bradüarütmia risk, tuleb jälgida sobivates kliinilistes tingimustes pidevalt 48 tundi.
English: Exposure to ledipasvir decreases with increasing body weight but the effect is not considered to be clinically relevant.
Estonian: Ekspositsioon ledipasviirile väheneb kehakaalu suurenemisel, kuid toimet ei peeta kliiniliselt oluliseks.
English: Skin disorders Frequency Not known: Stevens-Johnson syndrome
Estonian: Nahakahjustused Esinemissagedus teadmata: Stevensi-Johnsoni sündroom.
English: IL28 genotype
Estonian: IL28 genotüüp
English: Tell your doctor immediately if you are taking any medicines for heart problems and during treatment you experience:
Estonian: Teavitage oma arsti kohe, kui võtate ravimeid südameprobleemide tõttu ja ravi ajal esineb teil:
English: • you currently take, or have taken in the last few months, the medicine amiodarone to treat irregular heartbeats (your doctor may consider alternative treatments if you have taken this medicine).
Estonian: • võtate praegu või olete viimase paari kuu jooksul võtnud ravimit amiodaroon südame rütmihäirete raviks (kui olete seda ravimit juba võtnud, võib teie arst kaaluda alternatiivseid ravimeid).
English: Your doctor may need to increase the frequency of your blood tests to check how well your blood can clot.
Estonian: Teie arstil võib olla vajalik suurendada vereproovide tegemise sagedust, et kontrollida teie verehüübimist.
English: The most common variants were Q30R, Y93H and L31M.
Estonian: Kõige sagedamini esinenud variandid olid Q30R, Y93H ja L31M.
English: If you do miss a dose, work out how long it is since you last took your Harvoni:
Estonian: Kui teil jääb annus vahele, tehke kindlaks, kui palju aega on möödunud viimasest Harvoni võtmisest:
English: d Lack of pharmacokinetics interaction bounds 70-143%.
Estonian: d. Farmakokineetilise koostoime puudumine piirneb vahemikuga 70…143%.
English: The adverse reactions are listed below by body system organ class and frequency.
Estonian: Alltoodud kõrvaltoimed on klassifitseeritud organsüsteemide ja esinemissageduse kaupa.
English: Patients in these studies had compensated liver disease.
Estonian: Neis uuringuis osalenud patsientidel oli kompenseeritud maksahaigus.
English: g This study was conducted in the presence of another two direct-acting antiviral agents.
Estonian: g. See uuring viidi läbi veel kahe otsese toimega viirusvastase aine juuresolekul.
English: Each bottle contains a silica gel desiccant (drying agent) that must be kept in the bottle to help protect your tablets.
Estonian: Igasse pudelisse on kaasa pandud silikageelist desikant (kuivatusaine), mis tuleb jätta pudelisse, kuna see aitab kaitsta tablette.
English: Harvoni (administered alone or in combination with ribavirin) has no or negligible influence on the ability to drive and use machines.
Estonian: Harvoni (manustatuna eraldi või kombinatsioonis ribaviriiniga) ei mõjuta või mõjutab ebaoluliselt autojuhtimise ja masinate käsitsemise võimet.
English: It is important not to miss a dose of this medicine.
Estonian: On oluline, et te ei jäta selle ravimi annust vahele.
English: If you are taking one of these medicines your doctor will either give you a different medicine for stomach ulcers, heartburn or acid reflux, or recommend how and when you take that medicine.
Estonian: Kui te võtate ühte neist ravimitest, määrab teie arst teile erineva ravimi maohaavandite, kõrvetiste või happe tagasivoolu raviks või annab nõu, kuidas ja millal seda ravimit võtta.
English: Discontinue ribavirin if:
Estonian: Katkestage ribaviriini manustamine, kui:
English: These medicines can decrease the amount of ledipasvir in your blood.
Estonian: Need ravimid võivad langetada ledipasviiri sisaldust teie veres.
English: Contents of the pack and other information What Harvoni contains
Estonian: Pakendi sisu ja muu teave Mida Harvoni sisaldab
English: • If you are allergic to ledipasvir, sofosbuvir or any of the other ingredients of this medicine (listed in section 6 of this leaflet).
Estonian: • kui olete ledipasviiri, sofosbuviiri või selle ravimi mis tahes koostisosade (loetletud käesoleva infolehe lõigus 6) suhtes allergiline.
English: Subsequently, the marketing authorisation holder (MAH) shall submit PSUR for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Estonian: Seejärel peab müügiloa hoidja esitama ravimi perioodilisi ohutusaruandeid kooskõlas direktiivi 2001/83/EÜ artikli 107c punktis 7 sätestatud ja Euroopa ravimite veebiportaalis avaldatud liidu kontrollpäevade loetelu (EURD loetelu) nõuetega.
English: Evidence of slow oxidative metabolism via an unknown mechanism has been observed.
Estonian: Täheldati aeglast oksüdatiivset teadmata mehhanismi vahendusel toimuvat metabolismi.
English: What Harvoni looks like and contents of the pack
Estonian: Kuidas Harvoni välja näeb ja pakendi sisu
English: Patients were enrolled in one of the seven groups based on liver transplantation status and severity of hepatic impairment (see Table 17).
Estonian: Patsiendid määrati ühte seitsmest grupist, tuginevalt maksatransplantaadi staatusele ning maksakahjustuse raskusele (vt Tabel 17).
English: • If you or your partner become pregnant during Harvoni and ribavirin treatment or in the months that follow, you must contact your doctor immediately.
Estonian: • Kui teie või teie partner Harvoniga ja ribaviriiniga ravi ajal või sellele järgnevate kuude jooksul rasestub, informeerige sellest otsekohe oma arsti.
English: Race: Black/ African
Estonian: Rass: mustanahaline/afro ameeriklane
English: The active substances in the medicine work together by blocking two different proteins that the virus needs to grow and reproduce itself, allowing the infection to be permanently eliminated from the body.
Estonian: Ravimis sisalduvad toimeained toimivad koos, blokeerides kaht erinevat viiruse kasvamiseks ja paljunemiseks vajalikku valku, eemaldades seega infektsiooni organismist lõplikult.
English: 7% of liver transplant recipients had a modification of their immunosuppressive agents.
Estonian: 7%-l maksasiirdamise retsipientidest muudeti immunosuppressiivseid ravimeid.
English: That risk is even higher if ribavirin is used as part of the HCV treatment.
Estonian: See risk suureneb veelgi ribaviriini kasutamisel osana HCV-ravist.
English: The mechanism is not established.
Estonian: Mehhanism ei ole veel selge.
English: The effects of Harvoni during pregnancy are not known.
Estonian: Harvoni toime raseduse ajal ei ole teada.
English: * Patients lost to follow-up or who withdrew consent excluded.
Estonian: * Välja jäeti järelkontrollilt puudunud patsiendid ja nõusoleku tagasi võtnud patsiendid.
English: At the time of the interim analysis 40 patients have reached 12 weeks post treatment and SVR12 was 98% (39/40).
Estonian: Vaheanalüüsi ajaks oli 40 patsienti jõudnud ravijärgse 12. nädalani ja SVR12 oli 98% (39/40).
English: Your doctor will know if any of the following conditions apply to you.
Estonian: Teie arst teab, kui teil on ükskõik milline järgmistest seisunditest.
English: This includes:
Estonian: Nende hulka kuuluvad:
English: Reduce ribavirin dose to 600 mg/day if:
Estonian: Vähendage ribaviriini annus kuni 600 mg-ni/ööpäevas, kui:
English: It also contains lactose.
Estonian: Ravim sisaldab ka laktoosi.
English: a TE: number of treatment-experienced patients.
Estonian: a. TE: varem ravi saanud patsientide arv.
English: Swallow the tablet whole with or without food.
Estonian: Neelake tablett tervelt alla koos toiduga või ilma.
English: Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) or very rare (< 1/10,000).
Estonian: Esinemissagedused on määratletud järgmiselt: väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10), aeg-ajalt (≥ 1/1000 kuni < 1/100), harv (≥ 1/10 000 kuni < 1/1000) või väga harv (< 1/10 000).
English: Of the 155 patients enrolled, 1 patient discontinued treatment whilst on placebo.
Estonian: Uuringusse kaasatud 155 patsiendist 1 patsient katkestas ravi platseebo saamise ajal.
English: h Bioequivalence/Equivalence boundary 80-125%.
Estonian: h. Bioekvivalentsuse/samaväärsuse piir 80…125%.
English: Pharmacotherapeutic group: Direct-acting antiviral, ATC code: J05AP51
Estonian: Farmakoterapeutiline rühm: otsese toimega viirusvastased ained; ATC-kood: J05AP51
English: Lansoprazolee Rabeprazolee Pantoprazolee Esomeprazolee
Estonian: Lansoprasoole Rabeprasoole Pantoprasoole Esomeprasoole
English: • other liver problems apart from hepatitis C, for instance
Estonian: • Teised probleemid maksaga (lisaks C-hepatiidile), nt:
English: • swelling of the face, lips, tongue or throat (angioedema).
Estonian: • näo, huulte, keele või kõri turse (angioödeem).
English: 1200 mg/day
Estonian: 1200 mg ööpäevas
English: A coagulation test helps to identify patients with an increased bleeding risk due to increased dabigatran exposure.
Estonian: Koagulatsioonitest aitab tuvastada patsiente, kellel on dabigatraani suurema ekspositsiooni tõttu suurenenud veritsemisoht.
English: • The active substances are ledipasvir and sofosbuvir.
Estonian: • Toimeained on ledipasviir ja sofosbuviir.
English: If you take more Harvoni than you should
Estonian: Kui te võtate Harvonit rohkem, kui ette nähtud